Compare KRMD & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | ENTX |
|---|---|---|
| Founded | 1980 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.4M | 147.4M |
| IPO Year | 2019 | 2015 |
| Metric | KRMD | ENTX |
|---|---|---|
| Price | $3.00 | $3.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $6.25 | ★ $9.75 |
| AVG Volume (30 Days) | 165.1K | ★ 627.5K |
| Earning Date | 11-10-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | ★ $41,127,366.00 | $42,000.00 |
| Revenue This Year | $16.78 | N/A |
| Revenue Next Year | $17.22 | N/A |
| P/E Ratio | ★ N/A | $14.05 |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.86 | $0.91 |
| 52 Week High | $6.61 | $4.20 |
| Indicator | KRMD | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 63.60 |
| Support Level | $2.86 | $2.64 |
| Resistance Level | $3.41 | $3.26 |
| Average True Range (ATR) | 0.14 | 0.23 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 34.52 | 92.73 |
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.